Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 615-244-9 | CAS number: 71035-05-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Justification for type of information:
- Read across approach adequate to support 7.6.1 according to "Guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals" (ECHA 2008) and Read-Across Assessment
Framework (RAAF) (ECHA 2017)
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- read-across source
Reference
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Justification for type of information:
- Read across approach adequate to support 7.6.1 according to "Guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals" (ECHA 2008) and Read-Across Assessment
Framework (RAAF) (ECHA 2017) - Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- no guideline followed
- Species:
- rat
- Strain:
- other: CD (SD ) BR
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on study design:
- Groups of 25 mated female rats (203 to 256 g) were given daily dosages of 4.8 ml of deionized water (control), or 0.6, 1.2, 2.4, and 4.8 ml/kg/day of triethylene glycol monomethyl ether (TGME) by gavage. These doses corresponded to 0, 625, 1250, 2500 or 5000 mg/kg/day. All doses were adjusted daily according to body weights recorded immediately prior to intubation.
Rats were observed at least twice daily during the dosage and postdosage periods for clinical signs, signs of resorption, premature deliveries and death. Body weight and feed consumption were recorded on Day 0 of presumed gestation and from days 6 through 20 of gestation. Rats were euthanized on Day 20 of presumed gestation, and the thoracic and abdominal viscera were examined for gross lesions. The uterus was excised from each rat and weighed. The number and placement of implantations were recorded and sites were categorized as early or late resorptions, or
live or dead fetuses. Each ovary was examined for the number of corpora lutea. Fetuses were weighed, sexed, and examined for external alterations. One-half were examined for soft tissue alterations, and the remaining half were examined for skeletal alterations. Dams that were found dead were necropsied on day of death and subjected to the same procedures described for scheduled termination.
Maternal and fetal incidence data were analyzed using the variance test for homogeneity of the binomial distribution. Maternal body weight and feed consumption data, organ weight data, and litter averages for percent male fetuses, percent dead or resorbed conceptuses per litter, fetal body weights, fetal ossification sites, and percent fetal alterations were analyzed using Bartlett's Test of
homogeneity of variances and the analysis of variance (when data were homogeneous). If the analysis of variance was significant, Dunnett's Test was used to identify the statistical significance of individual groups. If data were not homogeneous, the Kruskal-Wallis test was used when less than or equal to 75% ties were present; when more than 75% ties were present the Fisher's Exact
Test was used. In cases where the Kruskal-Wallis Test was statistically significant, Dunn's Method of Multiple Comparisons was used to identify the statistical significance of individual groups.
All other Caesarean-sectioning data were evaluated using the procedures previously described for the Kruskal-Wallis Test. - Details on results:
- One nonpregnant animal in the high dose group (5000 mg/kg/day) was found dead on day 13 of presumed gestation. This was considered by the authors to be treatment-related. Significant numbers of rats treated with the high dose exhibited decreased motor activity, excess salivation, ataxia, and impaired righting reflex. Food consumption of high dose animals were reduced over the entire dosage period. Average maternal body weight gains of rats in the high dose group were
reduced on days 6-9, 6-12, 12-16, and 6-16 of gestation. Consequently, average body weights of these animals were reduced on days 9, 12, and 16. Average gravid uterine weights of high-dose animals were also reduced.
Food consumption of rats receiving 2500 mg/kg/day was reduced during days 6-16, 6-18, and 12-16. Food consumption and average maternal body weights and body weight gains in rats receiving 1250 mg/kg/day were not significantly different from controls. Therefore, 1250 mg/kg/day was considered by study personnel to be the NOAEL for maternal toxicity. - Details on maternal toxic effects:
- There was no effect of TGME on the number of pregnant dams or number of copora lutea, implantations, live litter size or fetal sex ratios.
- Dose descriptor:
- NOAEL
- Effect level:
- 1 250 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- mortality
- organ weights and organ / body weight ratios
- Details on embryotoxic / teratogenic effects:
- Foetal data (live/dead, sex, external defects, soft tissue and skeletal defects):
Significant increases in embryo-fetal lethality (litter averages for total resorptions (1.6 versus 0.6 in control), late resorptions (0.3 versus 0 in controls), percentage of resorbed con ceptuses (12.0 versus 4.4 in control) and dams with at least one resorption (81.8% versus 47.8 in control) occurred in the
5000 mg/kg group. Fetuses from rats treated with 2500 or 5000 mg/kg had lower body weights than controls (3.04 and 2.56 g (respectively) versus 3.32 in controls).
There was no effect of TGME on the incidences or types of gross external or internal soft tissue malformations. Groups given 1250 mg/kg/day and higher doses of TGME had significant increases
in the litter and/or fetal incidences of reversible delays in fetal ossification. Fetuses from rats given
2500 or 5000 mg/kg/day also had a significant increase in the incidence of cervical ribs. The NOAEL for developmental toxicity was considered by study personnel to be 625 mg/kg/day. - Dose descriptor:
- NOAEL
- Effect level:
- 625 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- reduction in number of live offspring
- fetal/pup body weight changes
- changes in litter size and weights
- skeletal malformations
- other: tissue malformation and fetal ossification
- Developmental effects observed:
- no
625 mg/kg bw/day is a conservative NOAEL based on specific doses used in the study.
The authors remarked that the skeletal variations noted were common observations in fetuses with reduced body weights. Since only reversible delays in fetal ossification were observed in the 1250 mg/kg/day group, the actual NOAEL may be close to this concentration
- Reason / purpose for cross-reference:
- read-across source
Reference
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Justification for type of information:
- Read across approach adequate to support 7.6.1 according to "Guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals" (ECHA 2008) and Read-Across Assessment
Framework (RAAF) (ECHA 2017) - Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- not specified
- GLP compliance:
- yes
- Limit test:
- no
- Specific details on test material used for the study:
- - Name of test material: Boric acid
- Analytical purity: > 99.7 %
- stability: Stable
- Lot/batch No.: 872703 - Species:
- rabbit
- Strain:
- New Zealand White
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Hazleton Research Products Inc., Denver, PA, USA
- Age at study initiation: 5 months of age
- Weight at study initiation: 2690-4380 g - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- VEHICLE
- Concentration in vehicle: 55 mg/mL boric acid
- Amount of vehicle: 5 mg/mL boric acid - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- no data
- Details on mating procedure:
- Impregnation procedure: Artificial insemination; designated Day 0
- Duration of treatment / exposure:
- Groups of 30 rabbits were used treated on Day 6 - 19 post-mating
- Frequency of treatment:
- no data
- Duration of test:
- terminate on day 30 of gestation
- Remarks:
- 0, 62.5, 125 or 250 mg/kg bw boric acid equivalent to 0, 10.9, 21.8 and 43.5 mg B/kg bw
- No. of animals per sex per dose:
- 30 females/group
- Control animals:
- yes
- Details on study design:
- no data
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
DETAILED CLINICAL OBSERVATIONS: Yes
BODY WEIGHT: Yes
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 30
- Organs examined: Uterus - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: No data
- Number of late resorptions: No data
- Other:
Uteri were stained with ammonium sulphide as no implantations were visible.
Litter size, number of dead foetuses and foetal weight were assessed. - Fetal examinations:
- - External examinations: Yes, including assessment for cleft palate
- Soft tissue examinations: Yes by dissection (Staples) and sex determined
- Skeletal examinations: Yes, all foetuses were skinned and cleaned and stained with alcian blue/alizarin red S
- Head examinations: Yes - Statistics:
- no data
- Indices:
- no data
- Historical control data:
- no data
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
Pregnant does exhibited no overt symptoms attributable to boric acid toxicity except in the high dose group. A decreased food intake (30 % reduction vs. controls during exposure period) and decreased maternal bodyweight were observed. Vaginal bleeding was noted at 43.5 mg B/kg bw between gestational days 19 - 30. All high-dose animals with vaginal bleeding had no live foetuses at sacrifice. At mid dose, increased body weight gain not clearly adverse. The authors considered 43.5 mg B/kg bw as the LOAEL for pregnant does and 21.8 mg B/kg bw as the NOAEL for maternal toxicity. - Dose descriptor:
- LOAEL
- Effect level:
- 250 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity - Based on reduced food intake, reduced body weight gain and abortions.
- Dose descriptor:
- NOAEL
- Effect level:
- 125 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- LOAEL
- Effect level:
- 250 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity - Based on increased resorptions and CVS malformations in surviving foetuses.
- Dose descriptor:
- NOAEL
- Effect level:
- 125 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Dose descriptor:
- LOAEL
- Effect level:
- 43.5 mg/kg bw/day
- Based on:
- element
- Basis for effect level:
- other: maternal toxicity - Based on reduced food intake, reduced body weight gain and abortions.
- Dose descriptor:
- NOAEL
- Effect level:
- 21.8 mg/kg bw/day
- Based on:
- element
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- LOAEL
- Effect level:
- 43.5 mg/kg bw/day
- Based on:
- element
- Basis for effect level:
- other: developmental toxicity - Based on increased resorptions and CVS malformations in surviving foetuses.
- Dose descriptor:
- NOAEL
- Effect level:
- 21.8 mg/kg bw/day
- Based on:
- element
- Basis for effect level:
- other: developmental toxicity
- Details on embryotoxic / teratogenic effects:
- Details on embryotoxic / teratogenic effects:
At the highest dose in this study of 250 mg/kg bw boric acid (43.5 mg B/kg bw/day), 90 % of implants/litter were resorbed compared to 6 % for controls, and 73 % had complete litter loss (0 % in controls). In the mid and low dose groups, no difference in percentage resorptions per litter was seen, compared to controls.
Average foetal bodyweight per litter was 92 % of the controls at the high dose (43.5-mg B/kg bw) but even at this exposure, it did not reach statistical significance possibly due to the low number of pups surviving (14 fetuses from 6 litters).
An increased incidence of malformed live foetuses/litter was observed at 43.5 mg B/kg bw, primarily due to cardiovascular defects (72 % for major defects of heart and/or great vessel in the high-dose group vs. 3 % in controls). In the mid and low dose groups, there was no increase in malformations per litter or total malformations. There were no variations between any groups concerning the incidence of skeletal malformations.
The only skeletal variations of interest was a dose related reduction in the incidence of extra ribs on Lumbar I which the authors did not consider to be toxicologically important.
Since no definitive developmental effects were observed in animals exposed to either 62.5 or 125 mg/kg bw boric acid (10.9 or 21.8 mg B/kg bw/day), the authors concluded that 125 mg/kg boric acid per day (21.8 mg B/kg bw/day) was the NOAEL for developmental toxicity. - Dose descriptor:
- NOAEL
- Effect level:
- >= 21.8 mg/kg bw/day (nominal)
- Based on:
- element
- Sex:
- male/female
- Basis for effect level:
- other: Since no definitive developmental effects were observed in animals exposed to 62.5 or 125 mg/kg bw boric acid (10.9 or 21.8 mg B/kg bw/day), it is concluded that 125 mg/kg boric acid per day (21.8 mg B/kg bw/day) was the NOAEL for developmental toxicity.
- Dose descriptor:
- NOAEL
- Effect level:
- >= 125 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Since no definitive developmental effects were observed in animals exposed to 62.5 or 125 mg/kg bw boric acid (10.9 or 21.8 mg B/kg bw/day), it is concluded that 125 mg/kg boric acid per day (21.8 mg B/kg bw/day) was the NOAEL for developmental toxicity.
- Abnormalities:
- not specified
- Developmental effects observed:
- not specified
- Conclusions:
- The highest dose was very toxic to dams and 90 % of implants were resorbed at the highest dose level, and 72 % of surviving foetuses had cardiac or great vessel malformations or increase in resorptions were reported in the mid and low dose groups.
Maternal effects
Parameter |
Study control data |
Low dose |
Medium dose |
High dose |
Number of dams examined |
30 |
30 |
30 |
30 |
Clinical findings during application of test substance |
|
|
|
reduced food and bodyweight |
Mortality of dams (%) |
0 |
1 |
1 |
0 |
Abortions |
0 |
0 |
0 |
3 |
Body weight gain day 6-19 day 0-30 |
93 357 |
132 493 |
97 543 |
-137* 226 |
Food consumption g/kg/day day 0-6 day 6-19 day 19-25 |
48.1 38.8 36.9 |
48.0 40.0 37.0 |
48.9 38.7 40.0 |
46.4 26.6* 44.9 |
Pregnancies % pregnant at sacrifice |
75 |
89 |
87 |
96 |
Necropsy findings in dams dead before end of test |
|
gavage error lungs |
stomach damage |
|
* P < 0.05.
Litter response (Caesarean section data)
Parameter |
Control data |
Low dose |
Medium dose |
High dose |
Corpora lutea number ±SEM mean No. per dam |
12.2 0.7 |
10.7 0.5 |
11.5 0.4 |
10.0* 0.7 |
Implantations sites per litter number ±SEM total/number of dams |
9.5 0.8 |
8.4 0.6 |
8.3 0.5 |
8.6 0.7 |
Resorptions % per litter % total/number of dams ±SEM |
6.3 2.4 |
5.9 1.9 |
7.7 2.1 |
89.9 5.0 |
total number of foetuses |
159 |
175 |
153 |
14 |
total number of litters |
18 |
23 |
20 |
6 |
live foetuses / litter number state ratio ±SEM |
8.8 0.8 |
7.6 0.6 |
7.7 0.5 |
2.3* 0.8 |
dead foetuses / litter % state ratio |
0 |
2.8 |
0.4 |
0 |
foetus weight (mean) weight (g) ±SEM |
44.8 1.5 |
46.5 1.4 |
45.7 1.2 |
41.1 2.7 |
Foetal sex ratio % male per litter ±SEM |
50 5 |
51 4 |
55 4 |
69 10 |
* P<0.05
Examination of the foetuses
Parameter |
Control data |
Low dose |
Medium dose |
High dose |
External malformations* % foetuses per litter ±SEM |
0.8 0.8 |
1.4 1.0 |
1.0 1.0 |
11.1* 8.2 |
External malformations No. of foetuses |
1 |
2 |
1 |
2 |
Skeletal malformations* % foetuses per litter ±SEM |
19.9 5.4 |
19.9 4.0 |
24.3 6.4 |
38.9 20.0 |
Skeletal malformations No. of foetuses |
30 |
39 |
44 |
4 |
Visceral malformations* % foetuses per litter ±SEM |
7.3 1.9 |
5.9 2.0 |
7.4 2.0 |
80.6* 16.3 |
Visceral malformations No. of foetuses |
13 |
11 |
12 |
11 |
% foetuses with cardiovascular % malformations ±SEM |
2.7 1.6 |
3.1 1.5 |
4.2 1.3 |
72.2* 16.5 |
*P<0.05
- Reason / purpose for cross-reference:
- read-across source
Reference
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Remarks:
- Structural analogy validated with Qsar Toolbox version 4.0
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The study is well documented and performed according to Charnoff and Kavlock screening method. In combination with the 28-day toxicity study , first indications on reproductive toxicity are avaialable.
- Justification for type of information:
- Read across approach adequate to support 7.6.1 according to "Guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals" (ECHA 2008) and Read-Across Assessment
Framework (RAAF) (ECHA 2017) - Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- other: Charnoff and Kavlock protocol
- Deviations:
- not applicable
- Remarks:
- 10 dams per group - dosing GD 7-17, pups followed to post partum day 5 of lactation.
- Principles of method if other than guideline:
- Charnoff, N. and Kavlock, R.J. (1981). A potential in vivo screen for the determination of teratogenic effects in mamals. Teratology, 21, 34A.
The method uses smaller numbers of litters, and no skeletal or visceral examination, but follow pups post-partum to day 5 of lation at which time dams and pups are necropsied for gross pathological lesions. - GLP compliance:
- yes
- Specific details on test material used for the study:
- Constituent
- Species:
- rat
- Strain:
- not specified
- Route of administration:
- oral: gavage
- Vehicle:
- not specified
- Frequency of treatment:
- daily
- Duration of test:
- lactation day 5
- Remarks:
- 0,25,150,1000 mg/kg bw/day
- No. of animals per sex per dose:
- 10 rats per group
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Other effects:
- no effects observed
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): no effects observed - Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- behaviour (functional findings)
- body weight and weight gain
- changes in pregnancy duration
- food consumption and compound intake
- mortality
- number of abortions
- total litter losses by resorption
- Reduction in number of live offspring:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Other effects:
- no effects observed
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- reduction in number of live offspring
- changes in litter size and weights
- Developmental effects observed:
- no
- Conclusions:
- the investigation concluded that the tested material is unlikely to be a teratogen
- Reason / purpose for cross-reference:
- read-across source
Reference
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Justification for type of information:
- Read across approach adequate to support 7.6.1 according to "Guidance on information requirements and chemical safety assessment Chapter R.6: QSARs and grouping of chemicals" (ECHA 2008) and Read-Across Assessment
Framework (RAAF) (ECHA 2017) - Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- not specified
- Species:
- rat
- Strain:
- other: Sprague-Dawley Crl: CD(SD) IGS BR
- Route of administration:
- oral: gavage
- Vehicle:
- other: Ethanol, 2-[2-(2-methoxyethoxy)ethoxy]-
- Duration of treatment / exposure:
- Exposure days: 15 days (Day 5 to Day 19 of gestation)
Post-exposure observation period: None - Remarks:
- 0 (control group) ,30,300,1000 mg/kg bw/day
- No. of animals per sex per dose:
- 8 animals in each group
- Control animals:
- yes
- Details on study design:
- The study was designed to evaluate the effects of the test item on embryonic and foetal development. Females were euthanized before delivery, on gestation Day 20. All animals were subjected to a full external and internal examination and any macroscopic abnormalities were recorded. The ovaries and uteri of pregnant animals were removed, examined and recoded with number of corpora lutea, number, position and type of intrauterine implantation, foetal sex, external foetal appearance, foetal weight, placental weight and gravid uterus weight.
- Details on maternal toxic effects:
- Mortality and Time to Death
All animals survived to the scheduled necropsies.
Effects on Dams
No signs of clinical toxicity were detected. No treatment related abnormalities were noted during the macroscopic examination of the pregnant animals at termination on Day 20 of gestation. - Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Basis for effect level:
- mortality
- Details on embryotoxic / teratogenic effects:
- Effects on Foetus
No treatment-related effects were noted for foetuses in treated animals when compared to control animals. - Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Basis for effect level:
- other: no effects specified
- Developmental effects observed:
- no
- Conclusions:
- The No Observed Effect Level (NOEL) was established as 1000 mg/kg bw/day in this study, based on the absence of treatment-related effects at any of the doses administered.
Data source
Reference
- Reference Type:
- publication
- Title:
- Developmental toxicity study with diethylene glycol dosed by gavage to CD rats and CD-1 mice
- Author:
- Ballantyne, B. and Snellings W.M.
- Year:
- 2 005
- Bibliographic source:
- Food and Chemical Toxicology 43 (2005) 1637–1646
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- 2-(2-hydroxyethoxy)ethan-1-ol
- Cas Number:
- 111-46-6
- Molecular formula:
- C4H10O3
- IUPAC Name:
- 2-(2-hydroxyethoxy)ethan-1-ol
- Details on test material:
- Constituent
Smile OCCOCCO
Constituent 1
- Specific details on test material used for the study:
- - obtained from Union Carbide Corporation, Hahnville, LA
- identification number: TFJ-44408 PL
- Purity : 99.87%.
- ethylene glycol content: 0.02 % , triethylene glycol: 0.11 %.
Test animals
- Species:
- mouse
- Strain:
- other:
- Remarks:
- Crl: CD-1 (ICR) BR
- Details on test animals or test system and environmental conditions:
- - Virgin male and virgin female [Crl: CD-1 (ICR) BR] outbred mice were obtained from Charles River Breeding Laboratories, Inc., Portage, MI.
- They were 42 days on arrival with males weighing 25–30 g, and females 23–25 g.
- During a 2-week acclimation period, they were housed one to three in stainless steel wire mesh cages.
- Food (Prolab Certified Ground Rodent Chow RMH-3220, Agway Inc., St. Marys, OH) and water were available ad libitum.
- Females were supplied water using water bottles having stainless steel sipper tubes to allow measurement of water consumption.
- Animals were assigned a unique number and identified by toe clipping and ear notching.
- Environmental temperature was maintained at 18–22 C, relative humidity at 40– 56%, and a 12-h photoperiod was used.
- Mice were mated, one male to one female, in stainless steel wire mesh cages.
- The day a dropped copulatory plug was found was designated gestation day (gd) 0.
- Thirty plug-positive females were assigned to each treatment group of the definitive study by a randomization procedure based on stratification on gd 0 body weights.
- The average body weight range of females at the start of the study was 25.07–25.27 g.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on mating procedure:
- Mice were mated, one male to one female, in stainless steel wire mesh cages. The day a dropped copulatory plug was found was designated gestation day (gd) 0. Thirty plug-positive females were assigned to each treatment group of the definitive study by a randomization procedure based on stratification on gd 0 body weights.
- Duration of treatment / exposure:
- Groups of 30 timed-pregnant CD-1 mice were dosed daily by gavage over gd 6–15 with undiluted DEG at dosages of 0.0 (controls), 0.5, 2.5 or 10.0 ml/kg/day (equivalent to 0, 559, 2795 and 11,180 mg/kg/day). Controls received 10 ml/kg/day of deionized (Milli-Q) water.
- Frequency of treatment:
- daily
- Duration of test:
- GD 6-15
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0.5 other: mL/Kg bw/day
- Remarks:
- equivalento to 559 mg/kg bw/day
- Dose / conc.:
- 2.5 other: mL/Kg bw/day
- Remarks:
- equivalento to 2795 mg/kg bw/day
- Dose / conc.:
- 10 other: mL/Kg bw/day
- Remarks:
- equivalento to 11180 mg/kg bw/day
- No. of animals per sex per dose:
- 30 mice per group
- Control animals:
- yes, concurrent vehicle
Examinations
- Maternal examinations:
- - All females were examined daily for any clinical signs of toxicity.
- They were weighed on gd 0, 6, 9, 12, 15 and 18, and body weight changes calculated for the interweighing periods.
- Food and water consumption was measured at sequential 3-day intervals over gd 0–18.
- All surviving females were sacrificed on gd 18 by CO2 asphyxiation.
- Midline thoracolaparotomy was performed, and the gravid uterus, ovaries, cervix, vagina, and abdominal and thoracic cavities examined grossly. - Ovaries and uterine content:
- - Corpora lutea were counted.
- Gravid uterine, liver, and kidney weights were recorded.
- The uterus was dissected longitudinally and all live and dead fetuses and resorption sites were recorded.
- Uteri that appeared non-gravid were placed in 10% ammonium sulfide for detection of early resorptions. - Fetal examinations:
- - Live fetuses were weighed, sexed, and examined for any external malformations or variations.
- All live fetuses in each litter were examined for thoracic and abdominal visceral abnormalities.
- One-half of the fetuses from each litter were decapitated and heads fixed in Bouins solution for examination of craniofacial structures by sectioning.- All fetuses (50% intact, 50% decapitated) were eviscerated, fixed in ethanol, processed for skeletal staining and examined for skeletal malformations and variations - Statistics:
- The unit of comparison was the pregnant female or litter (Weil, 1970). Results of quantitative continuous variables were intercompared for the DEG groups vs. the controls by Levenes test for equal variances (Levene, 1980), analyses of variance (ANOVA), and t-tests with Bonferroni probabilities for pairwise comparisons. When Levenes test indicted homogeneous variances, and the ANOVA was significant, a pooled t-test was used. When Levenes test indicated heterogeneous variances, all groups were compared with an ANOVA for unequal variances (Brown and Forsythe, 1974), followed by the separate variance t-test. Nonparametric data were statistically analyzed by the Kruskall–Walliss test, followed by the Mann–Whitney U-test. Incidence data were compared using Fishers Exact Test (Sokal and Rohlf, 1969). A probability value of p < 0.05 (two-tailed) was used as the critical level of significance for all tests.
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- There was maternal toxicity at 11180 mg/kg bw/day (mortality, signs, increased water consumption) and at 2795 mg/kg/day (increased water consumption).
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 559 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- clinical signs
- mortality
- water consumption and compound intake
Maternal abnormalities
- Abnormalities:
- no effects observed
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Implantations were comparable across all groups. Fetal body weights were significantly reduced at 11180 mg/kg bw/day. There were no increases in variations or malformations, either total, by category, or individually.
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 2 795 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- fetal/pup body weight changes
Fetal abnormalities
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Developmental effects observed:
- not specified
- Lowest effective dose / conc.:
- 11 180 mg/kg bw/day (nominal)
- Treatment related:
- yes
- Relation to maternal toxicity:
- not specified
- Dose response relationship:
- not specified
- Relevant for humans:
- no
Any other information on results incl. tables
developmental effects as secondary non specific consequence of maternal toxicity effects
Under the conditions of these studies, the no-observed-adverse effect-level (NOAEL) for DEG given by gavage over gd 6–15 was 559 mg/kg/day maternal toxicity, and 2795 mg/kg/day with mice for developmental toxicity (fetotoxicity).
There were no indications of embryotoxicity or teratogenic effects at any dosage.Applicant's summary and conclusion
- Conclusions:
- There were no indications of embryotoxicity or teratogenic effects at any dosage.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.